Jackie Hunter

Last updated

Jackie Hunter
Born
Ann Jacqueline Hunter [1]

1956 (age 67–68) [2]
Alma mater Bedford College, London
Known for
AI and Drug discovery
Awards
FRSB (2016)
Scientific career
Institutions
Thesis Chemical communication, aggression and sexual behaviour in the owl monkey (Aotus trivirgatus griseimembra)  (1981)
Website benevolent.ai/blog/

Ann Jacqueline Hunter CBE FMedSci FBPharmacolS FRSB is a British scientist who is a board director of BenevolentAI. [6] Hunter is also a visiting professor at St George's Hospital Medical School and Imperial College. She is Chair of the Trustees of the Sainsbury Laboratories at Norwich, chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix. She was previously CEO of the Biotechnology and Biological Sciences Research Council. [4] [7]

Contents

Education

Jackie Hunter was educated at Selwyn School, Matson, Gloucestershire and at the King's School, Gloucester. [8] She achieved a BSc in Physiology and Psychology at Bedford College, University of London in 1977 and whilst there represented the college on the TV programme University Challenge in 1976. She was awarded her PhD [9] for work carried out at London Zoo entitled 'Olfaction, aggression and sexual behaviour of owl monkeys (genus Aotus) [9] in 1981.

Career

Hunter undertook a Wellcome Trust Postdoctoral research fellowship at St George's Hospital Medical School before joining the pharmaceutical industry. She worked at Glaxo Laboratories first in Greenford and then Ware on novel therapeutics for Alzheimer's disease. In 1986 she moved to Astra and then subsequently in 1989 to SmithKline and French just prior to the merger that created SmithKlineBeecham (SB). At SB she held a number of management positions and was responsible for delivering a number of candidate molecules to development as well as large-scale external collaborations such as the ENU mutagenesis project with the MRC at Harwell. After the merger between SB and GlaxoWellcome to create GSK, she became head of the Neurology and GI Centre of Excellence for Drug Discovery and Site Head at the GSK site in Harlow, Essex.

In 2008, Hunter developed GSK's external innovation strategy and was responsible for developing the concept of the Stevenage Bioscience Catalyst and obtaining funding from government and other bodies.[ citation needed ] In 2010, she left GSK to establish OI Pharma Partners. [3] [4] [10] [11] [12] [13] [14] [15] which was established as a consultancy for the promotion of open innovation in the life sciences, working with governments, academic organisations and companies to formulate open innovation strategies and best practice.

In 2013, Hunter was appointed CEO of the BBSRC. [7] [16] [17] She has also been a non-executive director of Proximagen group plc and Chiltern International Group (2016–present). She was a member of the governing councils of Royal Holloway and Bedford College, University of London and of Hertfordshire University. In 2016 she left the BBSRC and joined Stratified Medical which became BenevolentAI, establishing the drug discovery arm of the organisation. She retired from BenevolentAI in 2020 but remains as a board director. In 2019 she was appointed chair of the trustees of the Sainsbury Laboratories at Norwich. In 2020 she was also appointed as chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix, an AI enabled imaging company.

Awards

Related Research Articles

<span class="mw-page-title-main">Orexin</span> Neuropeptide that regulates arousal, wakefulness, and appetite.

Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. It exists in the forms of orexin-A and orexin-B. The most common form of narcolepsy, type 1, in which the individual experiences brief losses of muscle tone, is caused by a lack of orexin in the brain due to destruction of the cells that produce it.

Sir Robert Brian Heap is a British biological scientist.

Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, is a non-departmental public body (NDPB), and is the largest UK public funder of non-medical bioscience. It predominantly funds scientific research institutes and university research departments in the UK.

<span class="mw-page-title-main">SB-649868</span> Chemical compound

SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia.

<span class="mw-page-title-main">Carole Goble</span> British computer scientist

Carole Anne Goble, is a British academic who is Professor of Computer Science at the University of Manchester. She is principal investigator (PI) of the myGrid, BioCatalogue and myExperiment projects and co-leads the Information Management Group (IMG) with Norman Paton.

<span class="mw-page-title-main">Janet Thornton</span> British bioinformatician and academic

Dame Janet Maureen Thornton, is a senior scientist and director emeritus at the European Bioinformatics Institute (EBI), part of the European Molecular Biology Laboratory (EMBL). She is one of the world's leading researchers in structural bioinformatics, using computational methods to understand protein structure and function. She served as director of the EBI from October 2001 to June 2015, and played a key role in ELIXIR.

The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).

<span class="mw-page-title-main">Hypocretin (orexin) receptor 1</span> Protein-coding gene in the species Homo sapiens

Orexin receptor type 1 (Ox1R or OX1), also known as hypocretin receptor type 1 (HcrtR1), is a protein that in humans is encoded by the HCRTR1 gene.

<span class="mw-page-title-main">Ottoline Leyser</span> English botanist (born 1965)

Dame Henrietta Miriam Ottoline Leyser is a British plant biologist and Regius Professor of Botany at the University of Cambridge who is on secondment as CEO of UK Research and Innovation (UKRI). From 2013 to 2020 she was the director of the Sainsbury Laboratory, Cambridge.

<span class="mw-page-title-main">Almorexant</span> Orexin antagonist compound

Almorexant (INN), also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials.

<span class="mw-page-title-main">Douglas Kell</span> British biochemist


Douglas Bruce Kell is a British biochemist and Professor of Systems Biology in the Institute of Systems, Molecular and Integrative Biology at the University of Liverpool. He was previously at the School of Chemistry at the University of Manchester, based in the Manchester Institute of Biotechnology (MIB) where he founded and led the Manchester Centre for Integrative Systems Biology (MCISB). He served as chief executive officer (CEO) of the Biotechnology and Biological Sciences Research Council (BBSRC) from 2008 to 2013.

<span class="mw-page-title-main">Suvorexant</span> Medication used to treat insomnia

Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. Its effectiveness is modest, and is similar to that of other orexin antagonists, but is lower than that of benzodiazepines and Z-drugs. Suvorexant is taken by mouth.

<span class="mw-page-title-main">Anne Glover (biologist)</span> Scottish biologist (born 1956)

Dame Lesley Anne Glover is a Scottish biologist and academic. She was Professor of molecular biology and cell biology at the University of Aberdeen before being named Vice Principal for External Affairs and Dean for Europe. She served as Chief Scientific Adviser to the President of the European Commission from 2012 to 2014. In 2018 she joined the Principal's senior advisory team at the University of Strathclyde.

An orexin receptor antagonist, or orexin antagonist, is a drug that inhibits the effect of orexin by acting as a receptor antagonist of one (selective orexin receptor antagonist or SORA) or both (dual orexin receptor antagonis or DORA) of the orexin receptors, OX1 and OX2. Medical applications include treatment of sleep disorders such as insomnia.

Emmanuel Mignot is a sleep researcher and director of the Stanford Center for Sleep Sciences and Medicine, at Stanford University. Dr. Mignot is an authority on sleep research and medicine, and is mostly known for his work on narcolepsy. He is the Craig Reynolds Professor of Sleep Medicine at Stanford Medical School, Stanford University.

<span class="mw-page-title-main">Trevor M. Jones</span>

Trevor Mervyn Jones, CBE PhD DSc (Hon) FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.

<span class="mw-page-title-main">Jane A. Langdale</span> British geneticist and academic

Jane Alison Langdale, is a British geneticist and academic. She is Professor of Plant Development in the Department of Biology at the University of Oxford and a Professorial Fellow at The Queen's College, Oxford.

<span class="mw-page-title-main">Moncef Slaoui</span> Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

Julia Clare Buckingham is a British pharmacologist, academic and academic administrator. She is the former Vice Chancellor of Brunel University London, UK.

<span class="mw-page-title-main">Masashi Yanagisawa</span> Japanese molecular biologist

Masashi Yanagisawa is a Japanese-American molecular biologist and physician, famous for his discovery of the hormone endothelin and the neuropeptide orexin, the absence of which is the cause of narcolepsy. He is currently the Director of the International Institute for Integrative Sleep Medicine, University of Tsukuba, and an adjunct professor at the Department of Molecular Genetics, University of Texas Southwestern Medical Center.

References

  1. ↑ Jackie Hunter's publications indexed by the Scopus bibliographic database. (subscription required)
  2. 1 2 3 "Royal Holloway, University of London Dr Jackie Hunter CBE (1956–)". Archived from the original on 24 September 2016. Retrieved 11 November 2013.
  3. 1 2 "OI Pharma Partners – Open Innovation in Healthcare". Archived from the original on 31 October 2013.
  4. 1 2 3 "Chief Executive's biography: Professor Jackie Hunter". Archived from the original on 4 December 2013.
  5. 1 2 "New Fellows | The Academy of Medical Sciences". Acmedsci.ac.uk. Archived from the original on 5 September 2015. Retrieved 7 June 2017.
  6. ↑ "Benevolent AI's Dr Jackie Hunter discusses defining innovation - Babraham Research Campus". www.babraham.com. Retrieved 8 January 2020.
  7. 1 2 Jackie Hunter to be next BBSRC chief, Times Higher Education, 4 June 2013
  8. ↑ "Jackie Hunter PhD CBE FBPharmacolS LinkedIn profile". Archived from the original on 8 November 2013.
  9. 1 2 Hunter, A. Jackie (1981). Chemical communication, aggression and sexual behaviour in the owl monkey (Aotus trivirgatus griseimembra) (PhD thesis). Bedford College, London.
  10. ↑ Hunter, J. (2011). "Challenges for pharmaceutical industry: New partnerships for sustainable human health". Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences. 369 (1942): 1817–1825. Bibcode:2011RSPTA.369.1817H. doi:10.1098/rsta.2010.0377. PMID   21464073.
  11. ↑ Hagan, J. J.; Leslie, R. A.; Patel, S.; Evans, M. L.; Wattam, T. A.; Holmes, S.; Benham, C. D.; Taylor, S. G.; Routledge, C.; Hemmati, P.; Munton, R. P.; Ashmeade, T. E.; Shah, A. S.; Hatcher, J. P.; Hatcher, P. D.; Jones, D. N.; Smith, M. I.; Piper, D. C.; Hunter, A. J.; Porter, R. A.; Upton, N. (1999). "Orexin a activates locus coeruleus cell firing and increases arousal in the rat". Proceedings of the National Academy of Sciences of the United States of America. 96 (19): 10911–10916. Bibcode:1999PNAS...9610911H. doi: 10.1073/pnas.96.19.10911 . PMC   17982 . PMID   10485925.
  12. ↑ Rogers, D. C.; Fisher, E. M.; Brown, S. D.; Peters, J.; Hunter, A. J.; Martin, J. E. (1997). "Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment". Mammalian Genome. 8 (10): 711–713. doi:10.1007/s003359900551. PMID   9321461. S2CID   29864514.
  13. ↑ Piper, D. C.; Upton, N.; Smith, M. I.; Hunter, A. J. (2000). "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats". The European Journal of Neuroscience. 12 (2): 726–730. doi:10.1046/j.1460-9568.2000.00919.x. PMID   10712652. S2CID   7052019.
  14. ↑ Brown, S. D. M.; Peters, P. M.; Strivens, J.; Rogers, M.; Hagan, D.; Spurr, J.; Gray, N.; Vizor, I. C.; Brooker, L.; Whitehill, D.; Washbourne, E.; Hough, R.; Greenaway, T.; Hewitt, S.; Liu, M.; McCormack, X.; Pickford, S.; Selley, K.; Wells, R.; Tymowska-Lalanne, C.; Roby, Z.; Glenister, P.; Thornton, P.; Thaung, C.; Stevenson, C.; Arkell, J. A.; Mburu, R.; Hardisty, P.; Kiernan, R.; Erven, A. (2000). "A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse". Nature Genetics. 25 (4): 440–443. doi:10.1038/78140. PMID   10932191. S2CID   9028853.
  15. ↑ Piper, D. C.; Upton, N.; Smith, M. I.; Hunter, A. J. (2000). "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats". European Journal of Neuroscience. 12 (2): 726–730. doi:10.1046/j.1460-9568.2000.00919.x. PMID   10712652. S2CID   7052019.
  16. ↑ "Bioscience innovation leader appointed as next BBSRC Chief Executive". Archived from the original on 4 December 2013.
  17. ↑ "Press release: New chief executive for the Biotechnology and Biological Sciences Research Council". Archived from the original on 14 May 2014.
Government offices
Preceded byIncumbent
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.